Federal Register / Vol. 81, No. 44 / Monday, March 7, 2016 / Notices 11791 

esubscription.asp to be notified via 

email of new filings and issuances 

related to this or other pending projects. 

For assistance, call 1–866–208–3676 or 

email FERCOnlineSupport@ferc.gov, for 

TTY, call (202) 502–8659. A copy is also 

available for inspection and 

reproduction at the address in item (h) 

above. Agencies may obtain copies of 

the application directly from the 

applicant. 

m. Individuals desiring to be included 

on the Commission’s mailing list should 

so indicate by writing to the Secretary 

of the Commission. 

n. Comments, Protests, or Motions to 

Intervene: Anyone may submit 

comments, a protest, or a motion to 

intervene in accordance with the 

requirements of Rules of Practice and 

Procedure, 18 CFR 385.210, .211, .214, 

respectively. In determining the 

appropriate action to take, the 

Commission will consider all protests or 

other comments filed, but only those 

who file a motion to intervene in 

accordance with the Commission’s 

Rules may become a party to the 

proceeding. Any comments, protests, or 

motions to intervene must be received 

on or before the specified comment date 

for the particular application. 

o. Filing and Service of Documents: 

Any filing must (1) bear in all capital 

letters the title ‘‘COMMENTS’’, 

‘‘PROTEST’’, or ‘‘MOTION TO 

INTERVENE’’ as applicable; (2) set forth 

in the heading the name of the applicant 

and the project number of the 

application to which the filing 

responds; (3) furnish the name, address, 

and telephone number of the person 

commenting, protesting or intervening; 

and (4) otherwise comply with the 

requirements of 18 CFR 385.2001 

through 385.2005. All comments, 

motions to intervene, or protests must 

set forth their evidentiary basis. Any 

filing made by an intervenor must be 

accompanied by proof of service on all 

persons listed in the service list 

prepared by the Commission in this 

proceeding, in accordance with 18 CFR 

385.2010. 

Dated: March 1, 2016. 

Nathaniel J. Davis, Sr., 

Deputy Secretary. 

[FR Doc. 2016–04961 Filed 3–4–16; 8:45 am] 

BILLING CODE 6717–01–P 

DEPARTMENT OF ENERGY 

National Nuclear Security 

Administration 

Defense Programs Advisory 

Committee 

AGENCY: National Nuclear Security 

Administration, Office of Defense 

Programs, Department of Energy. 

ACTION: Notice of closed meeting. 

SUMMARY: This notice announces a 

closed meeting of the Defense Programs 

Advisory Committee (DPAC). The 

Federal Advisory Committee Act (Pub. 

L. 92–463, 86 Stat. 770) requires that 

public notice of meetings be announced 

in the Federal Register. Due to national 

security considerations, under section 

10(d) of the Act and 5 U.S.C. 552b(c), 

the meeting will be closed to the public 

and matters to be discussed are exempt 

from public disclosure under Executive 

Order 13526 and the Atomic Energy Act 

of 1954, 42 U.S.C. 2161 and 2162, as 

amended. 

DATES: March 18, 2016, 8:30 a.m. to 5:00 

p.m. 

ADDRESSES: U.S. Department of Energy, 

1000 Independence Ave. SW., 

Washington, DC 20585. 

FOR FURTHER INFORMATION CONTACT: 

Loretta Martin, Office of RDT&E (NA– 

113), National Nuclear Security 

Administration, U.S. Department of 

Energy, 1000 Independence Ave. SW., 

Washington, DC 20585, (202) 586–7996. 

SUPPLEMENTARY INFORMATION: 

Background: The DPAC provides 

advice and recommendations to the 

Deputy Administrator for Defense 

Programs on the stewardship and 

maintenance of the Nation’s nuclear 

deterrent. 

Purpose of the Meeting: The purpose 

of this meeting of the DPAC is to 

finalize the Committee report to be 

provided to the National Nuclear 

Security Administration in response to 

its charge and to have initial discussion 

of the next charges to the Committee. 

Type of Meeting: In the interest of 

national security, the meeting will be 

closed to the public. The Federal 

Advisory Committee Act, 5 U.S.C. App. 

2, section 10(d), and the Federal 

Advisory Committee Management 

Regulation, 41 CFR 102–3.155, 

incorporate by reference the 

Government in the Sunshine Act, 5 

U.S.C. 552b, which, at 552b(c)(1) and 

(c)(3) permits closure of meetings where 

restricted data or other classified 

matters will be discussed. Such data 

and matters will be discussed at this 

meeting. 

Tentative Agenda: Welcome; reading 

of final draft of report; discussion of 

report, as necessary; (tentative) 

acceptance of report; discussion of next 

charges; conclusion. 

Public Participation: There will be no 

public participation in this closed 

meeting. Those wishing to provide 

written comments or statements to the 

Committee are invited to send them to 

Loretta Martin at the address listed 

above. 

Minutes: The minutes of the meeting 

will not be available. 

Issued in Washington, DC on March 2, 

2016. 

LaTanya R. Butler, 

Deputy Committee Management Officer. 

[FR Doc. 2016–04975 Filed 3–4–16; 8:45 am] 

BILLING CODE 6450–01–P 

ENVIRONMENTAL PROTECTION 

AGENCY 

[EPA–HQ–OPP–2008–0844; FRL–9942–69] 

Imidacloprid Registration Review; 

Draft Pollinator Ecological Risk 

Assessment; Extension of Comment 

Period 

AGENCY: Environmental Protection 

Agency (EPA). 

ACTION: Notice; extension of comment 

period. 

SUMMARY: EPA issued a notice in the 

Federal Register of January 15, 2016, 

opening a comment period for a draft 

pollinator-only ecological risk 

assessment for the registration review of 

imidacloprid. This document extends 

the comment period for 30 days, from 

March 15, 2016 to April 14, 2016. This 

comment period is being extended in 

response to a number of extension 

requests from various stakeholders. 

DATES: Comments, identified by docket 

identification (ID) number EPA–HQ– 

OPP–2008–0844, must be received on or 

before April 14, 2016. 

ADDRESSES: Follow the detailed 

instructions provided under ADDRESSES

in the Federal Register document of 

January 15, 2016 (81 FR 2212) (FRL– 

9940–82). 

FOR FURTHER INFORMATION CONTACT: 

Kelly Ballard, Pesticide Re-Evaluation 

Division (7508P), Office of Pesticide 

Programs, Environmental Protection 

Agency, 1200 Pennsylvania Ave. NW., 

Washington, DC 20460–0001; telephone 

number: (703) 305–8126; email address: 

ballard.kelly@epa.gov. 

SUPPLEMENTARY INFORMATION: 

This document extends the public 

comment period established in the 


asabaliauskas on DSK3SPTVN1PROD with NOTICES
11792 Federal Register / Vol. 81, No. 44 / Monday, March 7, 2016 / Notices 

1 In particular, the written request for confidential 

treatment that accompanies the comment must 

include the factual and legal basis for the request, 

and must identify the specific portions of the 

comment to be withheld from the public record. See 

FTC Rule 4.9(c), 16 CFR 4.9(c). 

Federal Register document of January 

15, 2016 (81 FR 2212) (FRL–9940–82). 

In that document, EPA opened a 

comment period for a draft pollinatoronly ecological risk assessment for the 

registration review of imidacloprid. EPA 

is hereby extending the comment 

period, which was set to end on March 

15, 2016, to April 14, 2016. 

To submit comments, or access the 

docket, please follow the detailed 

instructions provided under ADDRESSES

in the Federal Register document of 

January 15, 2016. If you have questions, 

consult the person listed under FOR

FURTHER INFORMATION CONTACT. 

Authority: 7 U.S.C. 136 et seq. 

Dated: February 29, 2016. 

Yu-Ting Guilaran, 

Director, Pesticide Re-Evaluation, Office of 

Pesticide Programs. 

[FR Doc. 2016–05033 Filed 3–4–16; 8:45 am] 

BILLING CODE 6560–50–P 

FEDERAL TRADE COMMISSION 

[File No. 151 0198] 

Hikma Pharmaceuticals PLC; Analysis 

To Aid Public Comment 

AGENCY: Federal Trade Commission. 

ACTION: Proposed Consent Agreement. 

SUMMARY: The consent agreement in this 

matter settles alleged violations of 

federal law prohibiting unfair methods 

of competition. The attached Analysis to 

Aid Public Comment describes both the 

allegations in the draft complaint and 

the terms of the consent orders— 

embodied in the consent agreement— 

that would settle these allegations. 

DATES: Comments must be received on 

or before March 29, 2016. 

ADDRESSES: Interested parties may file a 

comment at https://

ftcpublic.commentworks.com/ftc/

hikmaroxaneconsent online or on 

paper, by following the instructions in 

the Request for Comment part of the 

SUPPLEMENTARY INFORMATION section 

below. Write ‘‘In the Matter of Hikma 

Pharmaceuticals PLC,—Consent 

Agreement; File No. 151–0198’’ on your 

comment and file your comment online 

at https://ftcpublic.commentworks.com/

ftc/hikmaroxaneconsent by following 

the instructions on the Web-based form. 

If you prefer to file your comment on 

paper, write ‘‘In the Matter of Hikma 

Pharmaceuticals PLC,—Consent 

Agreement; File No. 151–0198’’ on your 

comment and on the envelope, and mail 

your comment to the following address: 

Federal Trade Commission, Office of the 

Secretary, 600 Pennsylvania Avenue 

NW., Suite CC–5610 (Annex D), 

Washington, DC 20580, or deliver your 

comment to the following address: 

Federal Trade Commission, Office of the 

Secretary, Constitution Center, 400 7th 

Street SW., 5th Floor, Suite 5610 

(Annex D), Washington, DC 20024. 

FOR FURTHER INFORMATION CONTACT: 

Jacqueline Mendel (202–326–2603), 

Bureau of Competition, 600 

Pennsylvania Avenue NW., Washington, 

DC 20580. 

SUPPLEMENTARY INFORMATION: Pursuant 

to Section 6(f) of the Federal Trade 

Commission Act, 15 U.S.C. 46(f), and 

FTC Rule 2.34, 16 CFR 2.34, notice is 

hereby given that the above-captioned 

consent agreement containing a consent 

order to cease and desist, having been 

filed with and accepted, subject to final 

approval, by the Commission, has been 

placed on the public record for a period 

of thirty (30) days. The following 

Analysis to Aid Public Comment 

describes the terms of the consent 

agreement, and the allegations in the 

complaint. An electronic copy of the 

full text of the consent agreement 

package can be obtained from the FTC 

Home Page (for February 26, 2016), on 

the World Wide Web, at http://

www.ftc.gov/os/actions.shtm. 

You can file a comment online or on 

paper. For the Commission to consider 

your comment, we must receive it on or 

before March 29, 2016. Write ‘‘In the 

Matter of Hikma Pharmaceuticals 

PLC,—Consent Agreement; File No. 

151–0198’’ on your comment. Your 

comment—including your name and 

your state—will be placed on the public 

record of this proceeding, including, to 

the extent practicable, on the public 

Commission Web site, at http://

www.ftc.gov/os/publiccomments.shtm. 

As a matter of discretion, the 

Commission tries to remove individuals’ 

home contact information from 

comments before placing them on the 

Commission Web site. 

Because your comment will be made 

public, you are solely responsible for 

making sure that your comment does 

not include any sensitive personal 

information, like anyone’s Social 

Security number, date of birth, driver’s 

license number or other state 

identification number or foreign country 

equivalent, passport number, financial 

account number, or credit or debit card 

number. You are also solely responsible 

for making sure that your comment does 

not include any sensitive health 

information, like medical records or 

other individually identifiable health 

information. In addition, do not include 

any ‘‘[t]rade secret or any commercial or 

financial information which . . . is 

privileged or confidential,’’ as discussed 

in Section 6(f) of the FTC Act, 15 U.S.C. 

46(f), and FTC Rule 4.10(a)(2), 16 CFR 

4.10(a)(2). In particular, do not include 

competitively sensitive information 

such as costs, sales statistics, 

inventories, formulas, patterns, devices, 

manufacturing processes, or customer 

names. 

If you want the Commission to give 

your comment confidential treatment, 

you must file it in paper form, with a 

request for confidential treatment, and 

you have to follow the procedure 

explained in FTC Rule 4.9(c), 16 CFR 

4.9(c).1 Your comment will be kept 

confidential only if the FTC General 

Counsel, in his or her sole discretion, 

grants your request in accordance with 

the law and the public interest. 

Postal mail addressed to the 

Commission is subject to delay due to 

heightened security screening. As a 

result, we encourage you to submit your 

comments online. To make sure that the 

Commission considers your online 

comment, you must file it at https://

ftcpublic.commentworks.com/ftc/

hikmaroxaneconsent by following the 

instructions on the Web-based form. If 

this Notice appears at http://

www.regulations.gov/#!home, you also 

may file a comment through that Web 

site. 

If you file your comment on paper, 

write ‘‘In the Matter of Hikma 

Pharmaceuticals PLC,—Consent 

Agreement; File No. 151–0198’’ on your 

comment and on the envelope, and mail 

your comment to the following address: 

Federal Trade Commission, Office of the 

Secretary, 600 Pennsylvania Avenue 

NW., Suite CC–5610 (Annex D), 

Washington, DC 20580, or deliver your 

comment to the following address: 

Federal Trade Commission, Office of the 

Secretary, Constitution Center, 400 7th 

Street SW., 5th Floor, Suite 5610 

(Annex D), Washington, DC 20024. If 

possible, submit your paper comment to 

the Commission by courier or overnight 

service. 

Visit the Commission Web site at 

http://www.ftc.gov to read this Notice 

and the news release describing it. The 

FTC Act and other laws that the 

Commission administers permit the 

collection of public comments to 

consider and use in this proceeding as 

appropriate. The Commission will 

consider all timely and responsive 

public comments that it receives on or 

before March 29, 2016. You can find 


asabaliauskas on DSK3SPTVN1PROD with NOTICES